Trium Capital LLP purchased a new stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 102,641 shares of the company's stock, valued at approximately $7,544,000. AstraZeneca makes up about 0.9% of Trium Capital LLP's investment portfolio, making the stock its 11th biggest holding.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of AZN. Cibc World Markets Corp boosted its stake in AstraZeneca by 1.1% during the fourth quarter. Cibc World Markets Corp now owns 12,901 shares of the company's stock valued at $845,000 after buying an additional 142 shares during the last quarter. CoreCap Advisors LLC boosted its position in AstraZeneca by 31.8% during the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock valued at $42,000 after acquiring an additional 155 shares in the last quarter. Oakworth Capital Inc. boosted its position in shares of AstraZeneca by 2.0% in the 1st quarter. Oakworth Capital Inc. now owns 8,575 shares of the company's stock worth $630,000 after purchasing an additional 167 shares in the last quarter. Spinnaker Investment Group LLC raised its stake in shares of AstraZeneca by 3.1% during the 1st quarter. Spinnaker Investment Group LLC now owns 5,754 shares of the company's stock valued at $423,000 after buying an additional 174 shares during the last quarter. Finally, Tiller Private Wealth Inc. raised its stake in shares of AstraZeneca by 5.7% during the 4th quarter. Tiller Private Wealth Inc. now owns 3,350 shares of the company's stock valued at $219,000 after buying an additional 181 shares during the last quarter. Institutional investors own 20.35% of the company's stock.
AstraZeneca Stock Performance
Shares of AZN traded down $0.68 during mid-day trading on Friday, hitting $71.13. 2,729,851 shares of the company's stock were exchanged, compared to its average volume of 5,261,949. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $87.68. The firm has a market capitalization of $220.60 billion, a P/E ratio of 28.57, a P/E/G ratio of 1.31 and a beta of 0.37. The business's 50 day moving average is $70.75 and its two-hundred day moving average is $70.75. The company has a current ratio of 0.90, a quick ratio of 0.70 and a debt-to-equity ratio of 0.65.
AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. The company had revenue of $13.59 billion during the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. During the same period last year, the company posted $2.06 earnings per share. On average, equities analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the company. BNP Paribas initiated coverage on AstraZeneca in a research note on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective for the company. Berenberg Bank set a $97.00 price target on AstraZeneca in a research note on Wednesday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, AstraZeneca presently has an average rating of "Moderate Buy" and an average price target of $89.00.
View Our Latest Stock Analysis on AZN
AstraZeneca Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
